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In a retrospective study of 19,171 mother-child dyads, elevated random plasma glucose 
values during early pregnancy were directly correlated with increased risk for CHD in 
offspring. Plasma glucose levels proximal to the period of cardiac development may 
represent a modifiable risk factor for CHD in expectant mothers without diabetes.
Maternal diabetes has long been recognized to be a risk factor for congenital heart disease 
(CHD) in offspring1,2. Despite the different pathophysiological mechanisms, both type 1 and 
type 2 diabetes contribute to the risk of CHD3, and although attenuated in women with 
improved glucose control, the risk of CHD does not revert to baseline 4,5. Population studies 
suggest the presence of acute diabetic complications during pregnancy significantly increase 
risk of all types of CHD in offspring1. Interestingly, a recent case-control study in non-
diabetic mothers displayed elevated random plasma glucose values during the second 
trimester in mothers of offspring with tetralogy of Fallot compared with mothers whose 
offspring did not have CHD6. These findings suggest that risk of CHD in the fetus conferred 
by maternal diabetes may be related to greater variations in plasma glucose levels in diabetic 
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mothers rather than, to long-term glucose values (HbA1c), plasma insulin level or a clinical 
diagnosis of diabetes. In addition, it raises the question of whether transient plasma glucose 
elevations even in non-diabetic mothers could predispose offspring for CHD.
Though studies of glucose metabolism performed during the second trimester appear to be 
strongly linked to glucose metabolism during both the peri-conceptional period and first 
trimester7–9 cardiac morphogenesis occurs during the first trimester between gestational 
weeks 4–1010. Most clinical measurements of glucose metabolism such as the oral glucose 
tolerance test (OGTT) are typically performed during the second trimester after the heart has 
already formed. Therefore we sought to determine if random non-fasting plasma glucose 
levels measured proximally to the period of cardiac development encompassing the first 
trimester were related to the risk of CHD both in diabetic and non-diabetic mothers.
Methods
We assembled a retrospective multi-institutional cohort of 19,107 mother-child dyads of 
mothers aged 16 or older for which prenatal information and postnatal diagnoses were 
available (Stanford Healthcare years 2009–2014 (n = 9,742), and Geisinger Health System 
years 2010–2015 (n = 9,365). We excluded offspring with a diagnosis of aneuploidy or 
22q11.2 deletion syndrome, multiple pregnancies, and women with extreme body mass 
index (BMI) measures (<15 or >50). Estimated dates of conception were interpolated in a 
hierarchical fashion from 280 days prior to birth, unless more specific data was available 
from icd9 codes (765.11–765.19) for prematurity status. Given some ambiguity in 
estimation of exact timing of laboratory measurements during pregnancy, we obtained all 
random plasma glucose measurements performed between four weeks prior to the estimated 
date of conception until the end of the 14th gestational week, and also results of the 1-hour 
oral glucose tolerance test (OGTT) typically completed during late second trimester. If 
multiple measurements were available, we selected the single highest value for analysis as 
delayed separation of the plasma can decrease the glucose value of the sample. We included 
plasma glucose measurements in our analysis, and specifically excluded glucose 
measurements designated as “fasting” or from glucose tolerance tests within the electronic 
medical record. Because insulin values are rarely measured as a component of routine 
clinical care, we did not incorporate insulin or other measures of insulin resistance within 
our analysis other than OGTT. A diagnosis of CHD was defined by the presence of any type 
of CHD (ICD9-codes 745.5–747.49) in the offspring. For individuals with OGTT and 
glucose measures, we performed logistic regression, and adjusted the model for known 
maternal risk factors for offspring with CHD, including presence of pregestational diabetes 
(defined by the presence of ICD9 codes 250–250.93), pre-pregnancy BMI, and maternal age 
at delivery. In a sensitivity analysis, we excluded mothers with pregestational diabetes. 
Power calculations were performed assuming an average glucose value of 89.3 mg/dL with a 
standard deviation of 6.2 mg/dL, demonstrating that in a group of 200 cases, 2000 controls 
displayed 80% power to detect an effect of 0.18 standard deviations between the 2 groups. 
Regression models were constructed using the R language for statistical computing.
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Results
Review of electronic medical records at both study institutions identified 811 CHD-affected 
pregnancies and 18,296 without CHD. At the Stanford site where detailed diagnostic 
information was available for review, all categories of CHD were represented with half of 
cases (49.9%, n = 223) constituting isolated ventricular or atrial septal defects. Relative to 
the Geisinger cohort, which is a community based health system, the mothers at the Stanford 
cohort were older, with higher BMI, and a greater burden of pre-pregnancy diabetes (Table 
I). Plasma glucose values were measured at least once in 11.9%, and OGTT in 49.7% of 
mothers. Mothers with measured plasma glucose values were younger than mothers without 
measurements (median 26 vs 28 years), and the same applied for OGTT values (median 26 
vs 30 years).
Among the women with relevant clinical measurements, higher plasma glucose (OR 1.08 
per 10 mg/dL increase in glucose, 95% CI:1.03–1.12, P < .001) and higher 1-hour OGTT 
values (OR 1.06, 95% CI:1.02–1.10, p = 0.002) were both associated with increased risk for 
CHD offspring in unadjusted logistic models. After adjustment for clinical correlates of 
glucose metabolism including maternal age, pre-pregnancy BMI, and the presence of 
preexisting maternal diabetes (Table 2), higher random first trimester plasma glucose values 
remained associated with increased risk for CHD (adjusted OR 1.08 per 10 mg/dL increase 
in glucose, 95% CI:1.02–1.13, p = 0.003) and the association with 1-hour OGTT values was 
elevated but not statistically significant (adjusted OR 1.03, 95% CI:0.98–1.07, p = 0.214). In 
a sensitivity analysis excluding women with a preexisting diagnosis of diabetes (n=74), the 
positive association between a random plasma glucose value with risk for CHD among 
offspring was essentially unchanged (adjusted OR 1.09, 95% CI:1.02–1.14, p = 0.003) 
(Table 2).
Discussion
Our observations demonstrate that higher random plasma glucose values measured during 
early pregnancy correlate with increased risk for CHD in offspring of mothers who do not 
have diabetes. Furthermore, plasma glucose measured during early pregnancy was more 
associated with risk for CHD in offspring, compared with the OGTT which is often used to 
risk-stratify pregnancies for fetal-echocardiographic screening.
Previous clinical observations detect increased risk for CHD in offspring even in diabetic 
mothers with well controlled glucose levels4,5, suggesting that the risk to offspring may be 
related to the variation in the plasma glucose levels. Although a lower HbA1c value reflects 
lower average glucose levels in the long term, fluctuation in glucose levels are likely higher 
in diabetic than in non-diabetic mothers. Transient high glucose is known to cause persistent 
epigenetic changes and altered gene expression in vascular cells during subsequent 
normoglycemia11. As cardiac development occurs early in pregnancy, and many important 
complex structures are formed during a short period of time, it is possible that even short 
elevations in glucose levels during critical time points can be enough to disturb cardiac 
development.
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The exact mechanisms by which high glucose may impact cardiac development are not yet 
clear. Maternal diabetes has been most strongly associated with conotruncal defects, such as 
tetralogy of Fallot3. High glucose and augmented oxidative stress have been observed to 
inhibit migration of neural crest derived cells from the neural tube in study animals, leading 
to congenital heart disease13,14. Thus, if the results from animal studies can be generalized 
to humans, transient elevations in glucose values during critical periods of cardiac 
development might potentially disturb the CNC migration even in embryos of non-diabetic 
mothers and contribute to the risk of CHD in the fetus.
Pre-diabetes is observed in as many as 28% of women of childbearing age 15. Given that 
increased risk for CHD continues to be measurable in women without a pre-existing 
diagnosis of diabetes both previously and now more fully in the data reported here, the 
contribution of maternal pre-diabetes to risk of CHD in offspring requires careful assessment 
in large prospective cohort studies. As plasma glucose levels are correlated with modifiable 
behaviors such weight, physical activity, and dietary habits, confirming these results in 
larger studies could provide additional data for pre- and early pregnancy health 
recommendations as a strategy to optimize the outcomes of pregnancy.
As a retrospective study, these findings are limited by bias inherent in selection of patients 
with glucose measurements and the ascertainment challenges inherent to working with data 
obtained from electronic medical records that did not include information on known risk 
factors for CHD such as maternal smoking, alcohol consumption, or infection. Early 
pregnancy plasma glucose measurements were present for only 13% of the mother-infant 
dyads, and the clinical reasoning for obtaining the glucose value was unknown, thus some 
values may be fasting or from other controlled states. The Geisinger cohort had individuals 
with multiple glucose measurements, which may be related to a bias toward more readily 
availability measurements from an integrated inpatient-outpatient electronic medical record. 
Indeed, the cohorts displayed differences attributable to the different roles that the 2 
institutions play within their respective healthcare markets. The older maternal age, higher 
BMI, higher rates of pre-existing diabetes and CHD are illustrative of a “higher-risk” 
maternal cohort, which reflects the role of Stanford Healthcare as a regional and statewide 
quaternary referral center. In contrast, the Geisinger cohort may represent a less selective 
population with an “average risk” for adverse outcomes. However, glucose values were 
measured in similar frequencies in pregnancies with or without CHD (12.3 % of dyads with 
CHD, 13.6 % of dyads without CHD), which does not suggest selection bias related to 
clinical suspicion of CHD or any known correlates. The overall size of the cohort was not 
adequately powered to characterize the risk for specific CHD malformations. As such, larger 
prospective studies are necessary to confirm the generalizability of these findings.
A random plasma glucose value performed early in pregnancy may be a marker for risk of 
CHD in offspring in non-diabetic mothers. Though strongly influenced by common genetic 
loci, plasma glucose levels are correlated with modifiable behaviors such weight, physical 
activity, and dietary habits. If confirmed in large population based studies, plasma glucose 
values may represent a modifiable risk factor for CHD in expectant mothers and women 
planning pregnancy and a biomarker applicable to risk-stratification of pregnant mothers for 
prenatal echocardiography screening for CHD in the fetus.
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